Sarcoma (Jan 2005)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

  • A. Poveda,
  • A. López-Pousa,
  • J. Martín,
  • J. García Del Muro,
  • R. Bernabé,
  • A. Casado,
  • C. Balañá,
  • O. Sanmartín,
  • M. D. Menéndez,
  • P. Escudero,
  • J. Cruz,
  • Elena Belyakova,
  • D. Menéndez,
  • J. M. Buesa

DOI
https://doi.org/10.1080/13577140500287024
Journal volume & issue
Vol. 9, no. 3-4
pp. 127 – 132

Abstract

Read online

Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR.